Skip to content

Protected: Studies

A Phase 2a Multi-­Center Study of 18F-­FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer’s Disease

Calendar Name FYN
Description The CONNECT study will test whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in mild-stage Alzheimer’s disease (AD). Although the cause of AD is unknown, several line
PI Borna
People Kristine Lipowski
Business Administrator -
Resources 3T Trio (Neuro)
IRB STU00200256
Start Date 2015-06-01
End Date 2018-07-01
Chart String 620-5404000-60041588
Affiliates No